Stockreport

ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer

ImmunoGen, Inc.  (IMGN) 
Last immunogen, inc. earnings: 5/1 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.immunogen.com/investor-relations
PDF Data from Avastin Cohort to be Presented at 2018 ASCO Annual Meeting Updated Data from Carboplatin Dose-Escalation Cohort Demonstrate Increased R [Read more]